



I. AMENDMENTS TO THE SPECIFICATION:

Please replace the paragraph beginning at page 1, line 24, with the following rewritten paragraph:

--At the present time glaucoma, including normal tension glaucoma, is treated by medically and/or surgically lowering elevated pressure; however, even when IOP is maintained ~~with in~~ within a normal range, visual field loss may progress. Degeneration involving retinal ganglion cells may be related to compression of the nerve fiber bundles, excitotoxicity, ischemia, or other as yet unrecognized ~~causitive~~ causative factors. Thus, factors other than IOP may play a role in determining both the occurrence and rate of progression of retinal ganglion cell death and subsequent visual field loss.—

Please replace the paragraph beginning at page 3, line 3, with the following rewritten paragraph:

--ADNF is believed to be useful to treat retinal and/or optic nerve head damage. As used herein ADNF refers to ADNF, ADNF peptides (including ADNF-9, ADNF-14), ADNF ~~peptidimemetics~~ peptidomimetics, ~~ANDF~~ ADNF small molecule analogues, and any agent that upregulates endogenous ADNF, or an expression vector which induces ADNF expression (Compounds). Retinal and/or optic nerve head damage can result from, e.g., glaucomatous optic neuropathy, ischemic optic neuropathies, ischemic retinal diseases, degenerative retinal diseases, retinal vein occlusion, retinal artery occlusion, diabetic retinopathy, and age-related macular degeneration (ARMD).--